Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. Nov 6, 2016; 7(4): 550-555
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.550
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.550
Table 6 Success rate and age: Primary eradication therapy
| Younger than 50 yr | Older than 50 yr | P value | ||
| ITT analysis | 67.8% (185/273) | 74.3% (1074/1446) | 0.03 | |
| PPI group | ||||
| PP analysis | 72.3% (185/256) | 77.2% (1074/1391) | 0.09 | |
| ITT analysis | 84.8% (50/59) | 86.2% (238/276) | 0.84 | |
| Vonoprazan group | ||||
| PP analysis | 92.6% (50/54) | 90.2% (238/264) | 0.8 |
- Citation: Yamada S, Kawakami T, Nakatsugawa Y, Suzuki T, Fujii H, Tomatsuri N, Nakamura H, Sato H, Okuyama Y, Kimura H, Yoshida N. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther 2016; 7(4): 550-555
- URL: https://www.wjgnet.com/2150-5349/full/v7/i4/550.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i4.550